Please login to the form below

Not currently logged in
Email:
Password:

Philippe Calais appointed CEO of Antisense Pharma

Joins as German biopharma aims to take cancer drug trabedersen to phase I

Philippe Calais - AntisenseDr Philippe Calais has joined the German biopharma Antisense Pharma as CEO.

Dr Calais replaces interim CEO Dr Hubert Heinrichs, who has held the position in addition to his role as chief medical officer since July, 2011.

One of his main tasks will be to ensure funding for the development of cancer drug trabedersen, which is planned to start phase I studies as a second-line treatment of pancreatic cancer.

“With Dr Calais, Antisense Pharma has gained an experienced global player in the pharmaceutical sector for its management board,” said Dr Heinrichs.

“During his professional career, he has been actively involved in all stages of the development of medicinal products, from discovery to clinical development, registration and commercialisation.”

This experience includes spells at Roche, where he was business unit head strategic marketing, and ICI Pharmaceuticals.

Other previous roles include CEO and president of Ambrilia Biopharma, president of global business at Neurochem and general manager at Servier Canada.

His most recent position was president and CEO of Canada-based Univalor.

“I am proud and honoured to join Antisense Pharma to lead the company's efforts in the new strategic direction,” Dr Calais commented. “Trabedersen's development package convinced me of the value of this drug candidate as I see its great potential in the fight against aggressive tumours.”

18th May 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...

Infographics